< Back to Newsroom

MultiCell Technologies Posts Journal Article on Research Leading to Company's Recent Patent Application on Novel Cancer Treatment Article in Prestigious Journal of Immunology Highlights Company's Progress to Treat Cancers for Potential Multibillion-Dollar Markets SAN DIEGO--(BUSINESS WIRE)--MultiCell Technologies, Inc. (OTCBB:MCET - News), developing first-in-class drugs based on advanced immune system modulation and other proprietary technologies, has posted a scientific article published in the Journal of Immunology on its web site describing the application of the Company's unique immune system modulation technology to treat cancer. The Company has made the article available to investors in the wake of its recent filing of a key patent relating to the application of its immune system-based technology to treat or control a range of malignant cancer tumors. MultiCell's drug candidate and proprietary technology MCT-465 is a key element of anti-tumor process discussed in the journal article and the patent application. MultiCell is an innovator in the science of modulating the human immune system with unique platform technologies, focusing on the development of breakthrough drugs to treat serious autoimmune diseases, including multiple sclerosis and type-1 diabetes, as well as influenza and cancer. Currently, the market for therapies that address these diseases is estimated at $8 billion worldwide. "Together with our industry leading collaborators, MultiCell has managed to discover new ways to understand and potentially treat widespread malignant tumors in cancer patients around the world," said Dr. Stephen Chang, Chief Executive Officer of MultiCell Technologies. "The research on MCT-465 and our other technologies covered in the Journal of Immunology article further validates our scientific and business model to develop drug candidates that work with the body's own immune system to deliver an entirely new generation of disease-specific immunotherapeutics." The Company's technology platforms include TLR and T-cell targeting to modulate both the innate and adaptive immune systems, thus enabling the creation of advanced drug candidates that stimulate or suppress the immune system via disease-specific targeting. The article, "Immunologic Control of Tumors by In Vivo Fcy Receptor-Targeted Antigen Loading in Conjunction with Double-Stranded RNA-Mediated Immune Modulation," details how MCET and its collaborators showed that the Company's technology resulted in control of tumor growth by modulating the immune system. The Journal of Immunology is owned and published by The American Association of Immunologists. The journal is cited more than any other immunology journal. Recently, MultiCell filed the patent application entitled, "Methods for Tumor Control and Treatment by Loading an Antigen Presenting Cell," which covers the use of MultiCell's proprietary dsRNA and Toll-like receptor (TLR) technology platform to combat malignant tumors in human patients. To read the entire scientific article, visit http://www.trilogy-capital.com/tcp/multicell. About MultiCell Technologies, Inc. MultiCell Technologies, Inc. is an integrated biopharmaceutical company committed to the development of breakthrough therapeutics based on a portfolio of therapeutic candidates and patented drug development technology. MultiCell's drug development program is focused on modulation of the immune system. The Company's lead drug candidates include drugs to treat MS-related chronic fatigue, relapsing-remitting multiple sclerosis, type-1 diabetes and infectious disease. The Company also holds unique cell-based technology for use in drug discovery screening applications, and is a leading producer of the cell lines needed by the biotechnology industry to develop new drugs and therapeutics. For more information about MultiCell Technologies, please visit http://www.MultiCelltech.com. For investor information about MultiCell, please visit http://www.trilogy-capital.com/tcp/multicell. For current stock price quotes and news, visit http://www.trilogy-capital.com/tcp/multicell/quote.html. To view the Company's Investor Fact Sheet, visit http://www.trilogy-capital.com/tcp/multicell/factsheet.html. To listen to an archived investor conference call, visit http://www.trilogy-capital.com/tcp/multicell/conference.html. Any statements in this press release about MultiCell's expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). These statements are often, but not always, made through the use of words or phrases such as "believe," "will,""expect," "anticipate," "estimate," "intend," "plan," "forecast," "could" and "would." Examples of such forward-looking statements include statements regarding developing products that address unmet medical needs. MultiCell bases these forward-looking statements on current expectations about future events. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by any forward-looking statement. Some of the risks, uncertainties and assumptions that could cause actual results to differ materially from estimates or projections in the forward-looking statement include, but are not limited to, the risk that we might not achieve our anticipated clinical development milestones, receive regulatory approval, or successfully commercialize our lead drug candidates as expected, the market for our products will not grow as expected, and the risk that our products will not achieve expectations. For additional information about risks and uncertainties MultiCell faces, see documents MultiCell files with the SEC, including MultiCell's report on Form 10-KSB for the fiscal year ended November 30, 2005, and all our quarterly and other periodic SEC filings. MultiCell claims the protection of the safe harbor for forward-looking statements under the Act and each assume no obligation and expressly disclaim any duty to update any forward-looking statement to reflect events or circumstances after the date of this news release or to reflect the occurrence of subsequent events. MultiCell Technologies, Inc. Dr. Stephen Chang, 858.200.0598 MCETInvestor@MultiCelltech.com or SmallcapInsights.com Dr. John Faessel, 858-587-8590 editors@smallcapinsights.com or Trilogy Capital Partners (Financial Communications) Paul Karon, 800-592-6067 paul@trilogy-capital.com Source: Business Wire (Wednesday November 1, 4:32 pm ET)